The study identified key lipid metabolism-related genes (LMGs) associated with nonalcoholic fatty liver disease (NAFLD) using transcriptomic and single-cell RNA sequencing (scRNA-seq) analyses. Researchers analyzed multiple datasets (GSE48452, GSE63067, GSE89632, GSE72756) alongside scRNA-seq data (GSE159977).
The study identified key lipid metabolism-related genes (LMGs) associated with nonalcoholic fatty liver disease (NAFLD) using transcriptomic and single-cell RNA sequencing (scRNA-seq) analyses. Researchers analyzed multiple datasets (GSE48452, GSE63067, GSE89632, GSE72756) alongside scRNA-seq data (GSE159977). They identified 295 differentially expressed genes (DEGs) between NAFLD and controls, with 24 LMGs linked to fatty acid metabolism, bile acid metabolism, and inflammation.
NAFLD patients were classified into two clusters based on these LMGs. Cluster 1 showed inhibited fatty acid metabolism but activated inflammatory and TNF signaling pathways, indicating disease heterogeneity. Using machine learning methods (LASSO, BSR, Boruta), three key LMGs—PRKAA2, KLF5, and ME1—were identified. ME1 and PRKAA2 were validated as core genes for diagnostic modeling, with ME1 showing stronger biological relevance. A two-gene diagnostic model integrating PRKAA2 and ME1 achieved high accuracy (AUC = 0.945).
Immune analysis revealed significant associations of ME1 and PRKAA2 with immune cells, especially NK and T cells, highlighting immune-metabolic crosstalk in NAFLD. scRNA-seq identified six cell types, with NK cells strongly correlating with ME1 expression. NAFLD samples showed reduced T-cell proportions but elevated NK-cell infiltration, indicating immune imbalance. ME1 was found to drive lipid accumulation and influence NK-cell metabolic activity, while PRKAA2's role was context-dependent.
Functional pathway analysis revealed that differential LMGs were involved in TNF, JAK–STAT, AMPK, and PPAR signaling, which regulate lipid metabolism and inflammation. The study underscores ME1’s potential as a biomarker and therapeutic target, linking lipid dysregulation and immune imbalance in NAFLD. Future studies should validate these findings and explore ME1’s therapeutic potential.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.